Effects of glucosamine administration on patients with rheumatoid arthritis

Rheumatology International

Volumn 27, Issue 3, 2007, Pages 213-218

  Nakamura, Hiroshi ^a   Masuko, Kayo ^b   Yudoh, Kazuo ^b   Kato, Tomohiro ^b   Kamada, Toshikazu ^c   Kawahara, Tohru ^d  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Hara Otrhopedic Hospital   (Japan)

^d Kawahara Clinic   (Japan)

Author keywords

Glucosamine; MMP 3; Rheumatoid arthritis

Indexed keywords

BUCILLAMINE; C REACTIVE PROTEIN; GLUCOSAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; STROMELYSIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PAIN ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHEUMATOID ARTHRITIS; SELF EVALUATION; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; ARTHRALGIA; ARTHRITIS, RHEUMATOID; DIETARY SUPPLEMENTS; FEMALE; GLUCOSAMINE; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33846159479     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-006-0197-1     Document Type: Article

References (18)

1. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C (2001) Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357:251-256
2. McAlindon TE, Laffalley MP, Gulin JP, Felson DT (2000) Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 283:1469-1475
3. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM et al (2006) Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354:795-808
4. Nakamura H, Nishioka K (2002) Effects of glucosamine/chondroitin supplement on osteoarthritis: involvement of PGE2 and YKL-40. Jpn J Rheumatol Surg 21:175-184
5. Nakamura H, Shibakawa A, Tanaka M, Kato T, Nishioka K (2002) Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol 22:293-299
6. Largo R, Alvarez-Soria MA, Diez-Ortego I, Calvo E, Sanchez-Pernaute O, Egido J, Herrero-Beaumont G (2003) Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthr Cartil 11:290-298
7. Byron CR, Orth MW, Venta PJ, Lloyd JW, Caron JP (2003) Influence of glucosamine on matrix metalloproteinase expression and activity in lipopolysaccharide-stimulated equine chondrocytes. Am J Vet Res 64:666-671
8. Dodge GR, Jimenez SA (2003) Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthr Cartil 11:424-232
9. Okada Y, Takeuchi N, Tomita K, Nakanishi I, Nagase H (1989) Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis. Ann Rheumatol Dis 48:645-53
10. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, Kamatani N (2000) Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43:852-858
11. Posthumus MD, Limburg PC, Westra J, Cats HA, Stewart RE, van Leeuwen MA, van Rijswijk MH (1999) Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology 38:1081-1087
12. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932-1939
13. Buchbinder R, Gingold M, Hall S, Cohen M (2002) Non-prescription complementary treatments used by rheumatoid arthritis patients attending a community-based rheumatology practice. Intern Med J 32:208-214
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
15. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727-735
16. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48
17. Lorish CD, Maisiak R. (1986) The Face Scale: a brief, nonverbal method for assessing patient mood. Arthritis Rheum 29:906-909
18. Thie NM, Prasad NG, Major PW (2001) Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial. J Rheumatol 28:1347-1355